PrimeGen Biotech LLC has created a wholly owned subsidiary, PrimeCell Therapeutics LLC, to focus on the development of PrimeCell(TM) adult, non-embryonic stem cell.

PrimeCell Therapeutics will focus solely on adult stem cell reprogramming, and preparing PrimeCell for therapeutic development and application. To date, using therapeutic reprogramming technology, human germ cells have been successfully transformed into human heart, brain, bone and cartilage cells. The PrimeCell findings currently are undergoing peer review, and the company has introduced its murine model and initial human results for PrimeCell at several global stem cell conferences.

The new company will operate in PrimeGen's research facility in Irvine, California, where PrimeGen continues to concentrate and develop regenerative therapeutics.

More about the spin off from Genetic Engineering News.